Refine
Year of publication
- 2021 (229) (remove)
Has Fulltext
- yes (229)
Is part of the Bibliography
- no (229)
Keywords
- BESIII (6)
- Branching fraction (3)
- e+-e− Experiments (3)
- COVID-19 (2)
- Initial state radiation (2)
- Lepton colliders (2)
- Particle decays (2)
- SARS-CoV-2 (2)
- Absolute branching fraction (1)
- Antibody avidity (1)
Institute
- Physik (217)
- Frankfurt Institute for Advanced Studies (FIAS) (113)
- Informatik (108)
- Medizin (12)
- Biochemie, Chemie und Pharmazie (1)
Using 5.9 pb−1 of e+e− annihilation data collected at center-of-mass energies from 3.640 to 3.701 GeV with the BESIII detector at the BEPCII Collider, we measure the observed cross sections of e+e−→K0SX (where X=anything). From a fit to these observed cross sections with the sum of continuum and ψ(3686) and J/ψ Breit-Wigner functions and considering initial state radiation and the BEPCII beam energy spread, we obtain for the first time the inclusive decay branching fraction B(ψ(3686)→K0SX)=(16.04±0.29±0.90)%, where the first uncertainty is statistical and the second is systematic.
Using a sample of 1.31×109 𝐽/𝜓 events collected with the BESIII detector, we perform a study of 𝐽/𝜓→𝛾𝜂𝜂𝜂′ to search for the 𝑋(2370) and 𝜂𝑐 in the 𝜂𝜂𝜂′ invariant mass distribution. No significant signal for the 𝑋(2370) is observed, and we set an upper limit for the product branching fraction of ℬ(𝐽/𝜓→𝛾𝑋(2370)·ℬ(𝑋(2370)→𝜂𝜂𝜂′)<9.2×10−6 at the 90% confidence level. A clear 𝜂𝑐 signal is observed for the first time, yielding a product branching fraction of ℬ(𝐽/𝜓→𝛾𝜂𝑐)·ℬ(𝜂𝑐→𝜂𝜂𝜂′)=(4.86±0.62(stat)±0.45(sys))×10−5.
Search for the reaction channel e⁺e⁻ → ηcηπ⁺π⁻ at center-of-mass energies from 4.23 to 4.60 GeV
(2021)
Using data collected with the BESIII detector operating at the Beijing Electron Positron Collider, we search for the process 𝑒+𝑒−→𝜂𝑐𝜂𝜋+𝜋−. The search is performed using five large datasets recorded at center-of-mass energies of 4.23, 4.26, 4.36, 4.42, and 4.60 GeV. The 𝜂𝑐 meson is reconstructed in 16 exclusive decay modes. No signal is observed in the 𝜂𝑐 mass region at any center-of-mass energy. The upper limits on the reaction cross sections are determined to be 6.2, 10.8, 27.6, 22.6 and 23.7 pb at the 90% confidence level at the center-of-mass energies listed above.
Observation of η′ → π⁺π⁻μ⁺μ⁻
(2021)
Using (1310.6±7.0)×106 𝐽/𝜓 events acquired with the BESIII detector at the BEPCII storage rings, the decay 𝜂′→𝜋+𝜋−𝜇+𝜇− is observed for the first time with a significance of 8𝜎 via the process 𝐽/𝜓→𝛾𝜂′. We measure the branching fraction of 𝜂′→𝜋+𝜋−𝜇+𝜇− to be ℬ(𝜂′→𝜋+𝜋−𝜇+𝜇−)=(1.97±0.33(stat)±0.19(syst))×10−5, where the first and second uncertainties are statistical and systematic, respectively
Based on 586 pb−1 of e+e− annihilation data collected at a center-of-mass energy of s√=4.6 GeV with the BESIII detector at the BEPCII collider, the absolute branching fraction of Λ+c→pK0Sη decays is measured for the first time to be B(Λ+c→pK0Sη)=(0.414±0.084±0.028)%, where the first uncertainty is statistical and the second is systematic. The result is compatible with a previous CLEO result on the relative branching fraction B(Λ+c→pK0Sη)B(Λ+c→pK−π+), and consistent with theoretical predictions of SU(3) flavor symmetry.
Born cross sections for the processes e+e− → ωη and e+e− → ωπ0 have been determined for centerof-mass energies between 2.00 and 3.08 GeV with the BESIII detector at the BEPCII collider. The results obtained in this work are consistent with previous measurements but with improved precision. Two resonant structures are observed. In the e+e− → ωη cross sections, a resonance with a mass of (2176 ± 24 ± 3) MeV/c2 and a width of (89 ± 50 ± 5) MeV is observed with a significance of 6.2σ. Its properties are consistent with the φ(2170). In the e+e− → ωπ0 cross sections, a resonance denoted Y (2040) is observed with a significance of more than 10σ. Its mass and width are determined to be (2034 ± 13 ± 9) MeV/c2 and (234 ± 30 ± 25) MeV, respectively, where the first uncertainties are statistical and the second ones are systematic.
The Born cross sections of the e+e− → +¯ − and e+e− → −¯ + processes are determined for centerof-mass energy from 2.3864 to 3.0200 GeV with the BESIII detector. The cross section lineshapes can be described properly by a pQCD function and the resulting ratio of effective form factors for the + and − is consistent with 3. In addition, ratios of the + electric and magnetic form factors, |GE /GM |, are obtained at three center-of-mass energies through an analysis of the angular distributions. These measurements, which are studied for the first time in the off-resonance region, provide precision experimental input for understanding baryonic structure. The observed new features of the ± form factors require more theoretical discussions for the hyperons.
We report an amplitude analysis and branching fraction measurement of 𝐷+
𝑠→𝐾+𝐾−𝜋+ decay using a data sample of 3.19 fb−1 recorded with BESIII detector at a center-of-mass energy of 4.178 GeV. We perform a model-independent partial wave analysis in the low 𝐾+𝐾− mass region to determine the 𝐾+𝐾− S-wave line shape, followed by an amplitude analysis of our very pure high-statistics sample. With the detection efficiency based on the amplitude analysis results, the absolute branching fraction is measured to be ℬ(𝐷+𝑠→𝐾+𝐾−𝜋+)=(5.47±0.08stat±0.13sys)%.
The cross sections of the process e+e−→K0SK0L are measured at fifteen center-of-mass energies s√ from 2.00 to 3.08 GeV with the BESIII detector at the Beijing Electron Positron Collider (BEPCII). The results are found to be consistent with those obtained by BaBar. A resonant structure around 2.2 GeV is observed, with a mass and width of 2273.7±5.7±19.3 MeV/c2 and 86±44±51 MeV, respectively, where the first uncertainties are statistical and the second ones are systematic. The product of its radiative width (Γe+e−) with its branching fraction to K0SK0L (BrK0SK0L) is 0.9±0.6±0.7 eV.
Based on 14.7 fb−1 of e+e− annihilation data collected with the BESIII detector at the BEPCII collider at 17 different center-of-mass energies between 3.7730 GeV and 4.5995 GeV, Born cross sections of the two processes e+e−→pp¯η and e+e−→pp¯ω are measured for the first time. No indication of resonant production through a vector state V is observed, and upper limits on the Born cross sections of e+e−→V→pp¯η and e+e−→V→pp¯ω at the 90% confidence level are calculated for a large parameter space in resonance masses and widths. For the current world average parameters of the ψ(4230) of m=4.2187 GeV/c2 and Γ=44 MeV, we find upper limits on resonant production of the pp¯η and pp¯ω final states of 7.5 pb and 10.4 pb at the 90% CL, respectively.
In Ref. [1] the BESIII collaboration published a cross section measurement of the process e+e− → π+π− in the energy range between 600 and 900 MeV. In this corrigendum, we report a corrected evaluation of the statistical errors in terms of a fully propagated covariance matrix. The correction also yields a reduced statistical uncertainty for the hadronic vacuum polarization contribution to the anomalous magnetic moment of the muon, which now reads as aππ,LO μ (600 − 900 MeV) = (368.2 ± 1.5stat ± 3.3syst) × 10−10. The central values of the cross section measurement and of aππ,LO μ , as well as the systematic uncertainties remain unchanged.
We report a measurement of the observed cross sections of e+ e− → J/ψX based on 3.21 fb − 1 of data accumulated at energies from 3.645 to 3.891 GeV with the BESIII detector operated at the BEPCII collider. In analysis of the cross sections, we measured the decay branching fractions of B(ψ(3686) → J/ψX) = (64.4 ± 0.6 ± 1.6)% and B(ψ(3770) → J/ψX) = (0.5 ± 0.2 ± 0.1)% for the first time. The energy-dependent line shape of these cross sections cannot be well described by two Breit-Wigner (BW) amplitudes of the expected decays ψ (3686) → J/ψX and ψ(3770) → J/ψX. Instead, it can be better described with one more BW amplitude of the decay R(3760)→ J/ψX. Under this assumption, we extracted the R (3760) mass M R (3760 ) = 3766.2 ± 3.8 ± 0.4 MeV/c2, total width Γ tot R ( 3760 ) = 22.2 ± 5.9 ± 1.4 MeV, and product of leptonic width and decay branching fraction
ΓeeR(3760) B[R(3760) → J/ψX] = (79.4 ± 85.5 ± 11.7) eV. The significance of the R(3760) is 5.3σ. The first uncertainties of these measured quantities are from fits to the cross sections and second systematic.
The first amplitude analysis of the decay D+s→K−K+π+π0 is presented using the data samples, corresponding to an integrated luminosity of 6.32 fb−1, collected with the BESIII detector at e+e− center-of-mass energies between 4.178 and 4.226 GeV. More than 3000 events selected with a purity of 97.5\% are used to perform the amplitude analysis, and nine components are found necessary to describe the data. Relative fractions and phases of the intermediate decays are determined. With the detection efficiency estimated by the results of the amplitude analysis, the branching fraction of D+s→K−K+π+π0 decay is measured to be (5.42±0.10stat.±0.17syst.)%.
We present the first amplitude analysis of the decay D+s→K−K+π+π0 using data samples of 6.32 fb−1 recorded with the BESIII detector between 4.178 and 4.226 GeV. More than 3000 events selected with a purity of 97.5\% are used to perform the amplitude analysis, and nine components are found necessary to describe the data. Relative fractions and phases of the intermediate decays are determined. With the detection efficiency determined by the results of the amplitude analysis, we measure the branching fraction of D+s→K−K+π+π0 decay to be (5.42±0.10stat.±0.17syst.)%.
We study ηc production at center-of-mass energies s√ from 4.18 to 4.60 GeV in e+e− annihilation data collected with the BESIII detector operating at the BEPCII storage ring, corresponding to 7.3 fb−1 of integrated luminosity. We measure the cross sections of the three different exclusive reactions e+e−→ηcπ+π−π0, e+e−→ηcπ+π−, and e+e−→ηcπ0γ. We find significant ηc production in e+e−→ηcπ+π−π0 at s√ of 4.23 GeV and 4.26 GeV and observe a significant energy-dependent Born cross section that we measure to be consistent with the production via the intermediate Y(4260) resonance. In addition, we perform a search for a charmonium-like Zc state close to the DD¯ threshold that decays to ηcπ, involving ground state charmonium, and observe no signal. Corresponding upper limits on the cross section of ηc and Zc production are provided, where the yields are not found to be significant.
The cross sections of the process e+e−→K0SK0L are measured at fifteen center-of-mass energies s√ from 2.00 to 3.08 GeV with the BESIII detector at the Beijing Electron Positron Collider (BEPCII). The results are found to be consistent with those obtained by BaBar. A resonant structure around 2.2 GeV is observed, with a mass and width of 2273.7±5.7±19.3 MeV/c2 and 86±44±51 MeV, respectively, where the first uncertainties are statistical and the second ones are systematic. The product of its radiative width (Γe+e−) with its branching fraction to K0SK0L (BrK0SK0L) is 0.9±0.6±0.7 eV.
Based on 14.7 fb−1 of e+e− annihilation data collected with the BESIII detector at the BEPCII collider at 17 different center-of-mass energies between 3.7730 GeV and 4.5995 GeV, Born cross sections of the two processes e+e−→pp¯η and e+e−→pp¯ω are measured for the first time. No indication of resonant production through a vector state V is observed, and upper limits on the Born cross sections of e+e−→V→pp¯η and e+e−→V→pp¯ω at the 90% confidence level are calculated for a large parameter space in resonance masses and widths. For the current world average parameters of the ψ(4230) of m=4.2187 GeV/c2 and Γ=44 MeV, we find upper limits on resonant production of the pp¯η and pp¯ω final states of 7.5 pb and 10.4 pb at the 90% CL, respectively.
Despite the recent availability of vaccines against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), there is an urgent need for specific anti-SARS-CoV-2 drugs. Monoclonal neutralizing antibodies are an important drug class in the global fight against the SARS-CoV-2 pandemic due to their ability to convey immediate protection and their potential to be used as both prophylactic and therapeutic drugs. Clinically used neutralizing antibodies against respiratory viruses are currently injected intravenously, which can lead to suboptimal pulmonary bioavailability and thus to a lower effectiveness. Here we describe DZIF-10c, a fully human monoclonal neutralizing antibody that binds the receptor-binding domain of the SARS-CoV-2 spike protein. DZIF-10c displays an exceptionally high neutralizing potency against SARS-CoV-2, retains full activity against the variant of concern (VOC) B.1.1.7 and still neutralizes the VOC B.1.351, although with reduced potency. Importantly, not only systemic but also intranasal application of DZIF-10c abolished the presence of infectious particles in the lungs of SARS-CoV-2 infected mice and mitigated lung pathology when administered prophylactically. Along with a favorable pharmacokinetic profile, these results highlight DZIF-10c as a novel human SARS-CoV-2 neutralizing antibody with high in vitro and in vivo antiviral potency. The successful intranasal application of DZIF-10c paves the way for clinical trials investigating topical delivery of anti-SARS-CoV-2 antibodies.
Objectives: Rising prevalence of multidrug-resistant organisms (MDRO) is a major health problem in patients with liver cirrhosis. The impact of MDRO colonization in liver transplantation (LT) candidates and recipients on mortality has not been determined in detail.
Methods: Patients consecutively evaluated and listed for LT in a tertiary German liver transplant center from 2008 to 2018 underwent screening for MDRO colonization including methicillin-resistant Staphylococcus aureus (MRSA), multidrug-resistant gram-negative bacteria (MDRGN), and vancomycin-resistant enterococci (VRE). MDRO colonization and infection status were obtained at LT evaluation, planned and unplanned hospitalization, three months upon graft allocation, or at last follow-up on the waiting list.
Results: In total, 351 patients were listed for LT, of whom 164 (47%) underwent LT after a median of 249 (range 0–1662) days. Incidence of MDRO colonization increased during waiting time for LT, and MRDO colonization was associated with increased mortality on the waiting list (HR = 2.57, p<0.0001. One patients was colonized with a carbapenem-resistant strain at listing, 9 patients acquired carbapenem-resistant gram-negative bacteria (CRGN) on the waiting list, and 4 more after LT. In total, 10 of these 14 patients died.
Conclusions: Colonization with MDRO is associated with increased mortality on the waiting list, but not in short-term follow-up after LT. Moreover, colonization with CRGN seems associated with high mortality in liver transplant candidates and recipients.
Background: Using data from the COHERE collaboration, we investigated whether primary prophylaxis for pneumocystis pneumonia (PcP) might be withheld in all patients on antiretroviral therapy (ART) with suppressed plasma human immunodeficiency virus (HIV) RNA (≤400 copies/mL), irrespective of CD4 count.
Methods: We implemented an established causal inference approach whereby observational data are used to emulate a randomized trial. Patients taking PcP prophylaxis were eligible for the emulated trial if their CD4 count was ≤200 cells/µL in line with existing recommendations. We compared the following 2 strategies for stopping prophylaxis: (1) when CD4 count was >200 cells/µL for >3 months or (2) when the patient was virologically suppressed (2 consecutive HIV RNA ≤400 copies/mL). Patients were artificially censored if they did not comply with these stopping rules. We estimated the risk of primary PcP in patients on ART, using the hazard ratio (HR) to compare the stopping strategies by fitting a pooled logistic model, including inverse probability weights to adjust for the selection bias introduced by the artificial censoring.
Results: A total of 4813 patients (10 324 person-years) complied with eligibility conditions for the emulated trial. With primary PcP diagnosis as an endpoint, the adjusted HR (aHR) indicated a slightly lower, but not statistically significant, different risk for the strategy based on viral suppression alone compared with the existing guidelines (aHR, .8; 95% confidence interval, .6–1.1; P = .2).
Conclusions: This study suggests that primary PcP prophylaxis might be safely withheld in confirmed virologically suppressed patients on ART, regardless of their CD4 count.